(reported by the Company)
No items found
GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas.
GlyTherix is developing Miltuximab® for the targeted treatment of a number of cancers. At the core of the technology is a protein known as Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, ovarian and brain cancers. It is not present in healthy tissue.
The company has a strong proprietary and Intellectual Property position covering both Miltuximab®, its anti-GPC-1 antibody and the antigen itself, GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope of cure.
GlyTherix has now completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse events observed. GlyTherix is interested in partnerships or collaborations with larger pharmaceutical partners.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):|
|Year of Commencement:||2017|
75 Talavera Rd, Suite 2, ground floor, Sydney, New South Wales 2113, AU
|State:||New South Wales|